ASH 2017 President’s meeting highlights
Results of Phase II trial to assess the efficacy and safety of idelalisib
ASPIRE update: promising results for MM
Which treatments are currently available for relapsed and refractory myeloma treatment?
PEP-C for lymphoma palliative care: a regional experience in the UK